Glucose Sensors Take Field Advantage

Gluco-Chaser unveils a working prototype for non-enzymatic electrochemical glucose sensors, that reportedly offers multiple advantages over existing glucose sensors. The Gluco-Chaser CGM offers flexibility in choosing a platform format, cost savings in production and storage (highly affordable end user pricing), and other technical features that improve user comfort level and hygiene. Notable, the CGM can be used daily for extended periods of time, which is useful for management of both Type 1 and Type 2 diabetes. The glucose detection mechanism and the corresponding electrode preparation methods are proprietary.

 

Advantages

Sponsored by Infosys

In Conversation with Antonio Neri, President & CEO – Hewlett Packard Enterprise & Salil Parekh, CEO – Infosys

Hear the CEOs of Infosys & HPE discuss the current crisis and how it has accelerated the need for digital transformation for their clients. Connectivity at the Edge, right mix of hybrid cloud, ability to extract data faster than ever before… these are just some of the contributions that HPE and Infosys make to our clients’ digital transformation journey.

 

Business Benefits: Unlike most glucose sensors, CGM does not require an unstable and expensive enzyme for glucose detection. This leads to huge cost savings in production and storage of the core sensing components. Gluco-Chaser technology is applicable to various formats of glucose monitors from conventional BGM to short-term (8 ~ 48 hours)- and long-term (3 ~ 7 days, and beyond) CGMs.

 

Usage Benefits: CGM offers the following features: (1) calibration-free operation of the sensor*; (2) 30-minute window for initial stabilization (competitors range anywhere from 3 to 12 hrs.); and (3) affordable pricing, comparable to that of conventional finger-prick sensors. This package of features has yet to be implemented by current market leaders, making it a smarter choice for Type-2 as well as Type-1 patients.

 

* Currently under development

 

Current achievements: (1) short initial stabilization time (30 minutes); (2) long sensor stability (immersed in human plasma for 1 month); (3) animal testing (EGA A+B > 90%); (4) elimination of noise from major interferents such as ascorbic acid, acetaminophen, and maltose; (5) BGM strip sensor under development (Whole blood tested; EGA A+B = 98%; journal publication in press).

 

For more top-secret info, contact Peter Lee via email at either [email protected] or [email protected] or go old school and call on the phone via +1-425-625-6724.

Suggested Articles

Originally a 1960s memory manufacturer, Intel wants out of NAND following the market decline in 2018

Process could be used to apply sensors detect symptoms for COVID-19, and the sensors could be reusable

From Sky Water Technology to Intel the message is the same: domestic chip production protects national security and jobs